101 related articles for article (PubMed ID: 38523704)
21. PEGylated therapeutics in the clinic.
Gao Y; Joshi M; Zhao Z; Mitragotri S
Bioeng Transl Med; 2024 Jan; 9(1):e10600. PubMed ID: 38193121
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics.
Lee Y; Jeong M; Park J; Jung H; Lee H
Exp Mol Med; 2023 Oct; 55(10):2085-2096. PubMed ID: 37779140
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA.
Li B; Jiang AY; Raji I; Atyeo C; Raimondo TM; Gordon AGR; Rhym LH; Samad T; MacIsaac C; Witten J; Mughal H; Chicz TM; Xu Y; McNamara RP; Bhatia S; Alter G; Langer R; Anderson DG
Nat Biomed Eng; 2023 Sep; ():. PubMed ID: 37679571
[TBL] [Abstract][Full Text] [Related]
24. Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy.
Wilhelmy C; Keil IS; Uebbing L; Schroer MA; Franke D; Nawroth T; Barz M; Sahin U; Haas H; Diken M; Langguth P
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631282
[TBL] [Abstract][Full Text] [Related]
25. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy.
Zhang Y; Hou X; Du S; Xue Y; Yan J; Kang DD; Zhong Y; Wang C; Deng B; McComb DW; Dong Y
Nat Nanotechnol; 2023 Nov; 18(11):1364-1374. PubMed ID: 37500773
[TBL] [Abstract][Full Text] [Related]
26. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
Kozma GT; Mészáros T; Berényi P; Facskó R; Patkó Z; Oláh CZ; Nagy A; Fülöp TG; Glatter KA; Radovits T; Merkely B; Szebeni J
Vaccine; 2023 Jul; 41(31):4561-4570. PubMed ID: 37330369
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
Zhou ZH; Cortese MM; Fang JL; Wood R; Hummell DS; Risma KA; Norton AE; KuKuruga M; Kirshner S; Rabin RL; Agarabi C; Staat MA; Halasa N; Ware RE; Stahl A; McMahon M; Browning P; Maniatis P; Bolcen S; Edwards KM; Su JR; Dharmarajan S; Forshee R; Broder KR; Anderson S; Kozlowski S
Vaccine; 2023 Jun; 41(28):4183-4189. PubMed ID: 37244808
[TBL] [Abstract][Full Text] [Related]
28. PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R; Sasso JM; Zhou QA
Bioconjug Chem; 2023 Jun; 34(6):941-960. PubMed ID: 37162501
[TBL] [Abstract][Full Text] [Related]
29. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
30. Polysarcosine-based lipid formulations for intracranial delivery of mRNA.
Bi D; Unthan DM; Hu L; Bussmann J; Remaut K; Barz M; Zhang H
J Control Release; 2023 Apr; 356():1-13. PubMed ID: 36803765
[TBL] [Abstract][Full Text] [Related]
31. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
[TBL] [Abstract][Full Text] [Related]
32. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines.
Ju Y; Carreño JM; Simon V; Dawson K; Krammer F; Kent SJ
Nat Rev Immunol; 2023 Mar; 23(3):135-136. PubMed ID: 36539526
[TBL] [Abstract][Full Text] [Related]
33. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
Carreño JM; Singh G; Tcheou J; Srivastava K; Gleason C; Muramatsu H; Desai P; Aberg JA; Miller RL; Study Group P; Pardi N; Simon V; Krammer F
Vaccine; 2022 Oct; 40(42):6114-6124. PubMed ID: 36115801
[TBL] [Abstract][Full Text] [Related]
34. Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration.
Guerrini G; Gioria S; Sauer AV; Lucchesi S; Montagnani F; Pastore G; Ciabattini A; Medaglini D; Calzolai L
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012103
[TBL] [Abstract][Full Text] [Related]
35. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8
Chen J; Ye Z; Huang C; Qiu M; Song D; Li Y; Xu Q
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2207841119. PubMed ID: 35969778
[TBL] [Abstract][Full Text] [Related]
36. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.
Cui Z; Zeng C; Huang F; Yuan F; Yan J; Zhao Y; Zhou Y; Hankey W; Jin VX; Huang J; Staats HF; Everitt JI; Sempowski GD; Wang H; Dong Y; Liu SL; Wang Q
Nat Chem Biol; 2022 Oct; 18(10):1056-1064. PubMed ID: 35879545
[TBL] [Abstract][Full Text] [Related]
37. The role of lipid components in lipid nanoparticles for vaccines and gene therapy.
Hald Albertsen C; Kulkarni JA; Witzigmann D; Lind M; Petersson K; Simonsen JB
Adv Drug Deliv Rev; 2022 Sep; 188():114416. PubMed ID: 35787388
[TBL] [Abstract][Full Text] [Related]
38. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
[TBL] [Abstract][Full Text] [Related]
39. Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy.
McSweeney MD; Mohan M; Commins SP; Lai SK
Front Allergy; 2021; 2():715844. PubMed ID: 35387046
[TBL] [Abstract][Full Text] [Related]
40. mRNA vaccines for COVID-19 and diverse diseases.
Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
